Norio Akuta
Minato, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 212 publications
ASO Visual Abstract: Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab.
Journal: Annals of surgical oncology
Published: August 01, 2026
Serum microRNA-122 Is Associated with the Therapeutic Response to Diet and Exercise Therapy in Patients with Steatotic Liver Disease.
Journal: Internal medicine (Tokyo, Japan)
Published: May 06, 2026
Prognostic Benefit of Sequential Locoregional Interventions During First-Line Systemic Therapy for Hepatocellular Carcinoma: Insights from Interaction Analysis of Lenvatinib and Atezolizumab/Bevacizumab.
Journal: Annals of surgical oncology
Published: April 24, 2026
Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: April 03, 2026
Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.
Journal: Journal of gastroenterology
Published: February 21, 2026
Metastasis of Hepatocellular Carcinoma to the Urinary Bladder: A Case Report and Literature Review.
Journal: IJU case reports
Published: February 09, 2026
Serum MicroRNA-122 Predicts Early Progressive Disease in Unresectable Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Therapy.
Journal: Oncology
Published: January 22, 2026
Guidance for Liver Rehabilitation in Chronic Liver Disease.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: September 02, 2025
Chemoprevention of hepatocellular carcinoma by next-generation antipsychotic aripiprazole.
Journal: Hepatology (Baltimore, Md.)
Published: August 13, 2025
Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis.
Journal: Liver cancer
Published: May 19, 2025
Evidence based medical care of MASLD/MASH -Future perspective of Japanese guideline
Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
Published: May 11, 2025
Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
Journal: Journal of gastroenterology
Published: March 21, 2025
Last Updated: 09/26/2026